Psychedelic medicine is moving from underground experimentation into mainstream investment and clinical research, backed by some of Silicon Valley's most influential figures and top-tier medical institutions. A wave of billionaire-backed funding and groundbreaking trials suggest that compounds like psilocybin and MDMA could reshape how doctors treat depression, trauma, and even cancer-related nerve damage within the next few years.

Why Are Tech Billionaires Suddenly Investing in Psychedelics?

Elon Musk's inner circle has emerged as a major force in psychedelic therapeutics, with several prominent figures directing substantial capital toward drug development companies. Antonio Gracias, a longtime Musk ally and former Tesla board director, made a bid earlier this year to acquire a controlling stake in Lykos Therapeutics, the pharmaceutical company working to bring MDMA-assisted therapy to market for post-traumatic stress disorder (PTSD) treatment.

Gracias's involvement reportedly began with a chance meeting at Burning Man with Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies, the nonprofit research organization that originally created Lykos Therapeutics. Beyond Lykos, Gracias has also directed philanthropic resources toward academic research; in 2023, the Gracias Family Foundation gifted funds to Harvard University to establish a program dedicated to the Study of Psychedelics in Society and Culture.

Gracias is far from alone. PayPal co-founder Peter Thiel is a major investor in Atai Life Sciences, a biotechnology company with a significant stake in Compass Pathways, which focuses on developing psilocybin-based therapies for treatment-resistant depression. Google co-founder Sergey Brin has helped fund Soneira, a startup developing psychedelic treatments based on ibogaine, a compound derived from the iboga plant that shows promise for treating addiction. OpenAI chief executive Sam Altman has also invested in psychedelic therapy companies and discussed his own experiences with psychedelics helping him manage anxiety.

The broader investment landscape reflects this momentum. Venture capital fund Palo Santo closed a $50 million fund dedicated specifically to backing emerging psychedelic therapeutics companies, with a portfolio spanning more than 20 companies across the psychedelics ecosystem.

What New Medical Applications Are Being Tested?

Beyond psychiatric and trauma treatment, psychedelics are entering oncology. MD Anderson Cancer Center, one of the United States' leading cancer hospitals, is preparing to launch a clinical trial investigating psilocybin's potential to prevent or reduce neurotoxicity caused by chemotherapy. This represents a notable shift in how psychedelics are being studied, moving beyond mental health into supportive cancer care.

The trial will enroll patients undergoing neurotoxic chemotherapy regimens, such as those involving platinum-based agents or taxanes, which are known to cause peripheral neuropathy (nerve damage) and cognitive impairment in a substantial proportion of cancer patients. Psilocybin, a serotonergic psychedelic, has demonstrated neuroplastic and anti-inflammatory effects in preclinical models. The hypothesis is that psilocybin may mitigate chemotherapy-induced neuronal damage by promoting neurogenesis and reducing neuroinflammation.

A 2024 study in rodents exposed to cisplatin, a common chemotherapy drug, found that 5-HT2A agonists (compounds that activate serotonin receptors) reduced markers of neuronal cell death and improved behavioral outcomes. However, translation to human oncology patients remains untested, and the precise dosing, safety profile, and interaction with chemotherapeutic agents are unknown.

How Are Regulatory and Investment Barriers Shifting?

The renewed institutional and celebrity interest in psychedelics comes amid a broader cultural shift in how the drugs are perceived, following decades in which they remained largely relegated to underground or recreational use after their prohibition in the 1970s. Oregon and Colorado, along with several U.S. cities, have moved to decriminalize psilocybin, the active compound found in magic mushrooms, with Oregon going further to legalize its supervised use.

Pharmaceutical companies have also found commercial success with related compounds already approved for medical use. Johnson & Johnson's nasal esketamine treatment, Spravato, became the company's fastest-growing product at one point, generating hundreds of millions of dollars in sales within a single nine-month period.

Despite the growing enthusiasm and capital flowing into the sector, the regulatory path for psychedelic-assisted therapies remains uncertain. The FDA denied Lykos Therapeutics' application to market MDMA for PTSD treatment in 2024, citing inadequate clinical trial data. That setback has not deterred figures like Gracias and British hedge fund manager Sir Christopher Hohn, who leads TCI Fund Management with more than $60 billion in assets under management, from continuing to pursue investment in the company, betting that additional clinical trial data and continued advocacy could eventually clear the path toward regulatory approval.

What Experts Say About the Future of Psychedelic Medicine

Industry leaders frame the investment wave as a response to a growing global mental health crisis. Palo Santo co-founder Tim Schlidt stated the fund's mission clearly:

"Against the backdrop of a growing global mental health crisis, our mission is to drive clinical development and FDA approval of these much-needed therapies that we believe will become the future standard of care."

Tim Schlidt, Co-founder, Palo Santo

Julie Holland, a physician and adviser to the Palo Santo fund, echoed that sense of urgency:

"It's crucial that the most promising companies and therapies receive the funding needed to advance psychedelic medicines through clinical trials in a timely manner, and I am proud to be part of a team of experts who share that same goal."

Julie Holland, Physician and Adviser, Palo Santo

Steps to Understanding Psychedelic Medicine's Role in Your Health

• Know the Current Approvals: Only one psychedelic compound, esketamine (Spravato), is currently FDA-approved for medical use, specifically for treatment-resistant depression. Most other psychedelics remain in clinical trials or under investigation.
• Understand the Research Pipeline: MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for depression are in advanced clinical trials, with regulatory decisions expected in coming years. MD Anderson's oncology trial represents an entirely new frontier for psychedelic research.
• Recognize the Investment Momentum: Billions in venture capital and billionaire backing suggest that psychedelic therapies will likely become more widely available and accessible within the next 5 to 10 years, assuming regulatory approval continues.
• Be Aware of Risks and Unknowns: Drug-drug interactions between psychedelics and other medications, effects in immunocompromised patients, and long-term safety data in diverse populations remain areas requiring further study before widespread adoption.

The involvement of MD Anderson, a National Cancer Institute-designated comprehensive cancer center, lends significant credibility to the exploration of psychedelics for medical uses outside of mental health. If the trial demonstrates safety and efficacy, it could catalyze a wave of research into psilocybin and related compounds for supportive care in oncology and neurology, and may influence the FDA to consider broader medical indications for psychedelics.

With billionaires spanning the technology, finance, and artificial intelligence industries now directing substantial personal wealth toward psychedelic drug development, alongside dedicated venture funds building out broader portfolios across the sector, the psychedelics industry appears positioned to continue attracting significant capital in the years ahead. The key question is not whether psychedelics will enter mainstream medicine, but how quickly and thoroughly these compounds can move from high-profile private investment into broadly accessible, FDA-approved medical treatments.